n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's "Dead Cat Bounce" Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "dead cat bounce" (down big yesterday but up big today) candidate

ARIAD Announces Phase 2 Dose-Ranging Trial Of Iclusig (Ponatinib) To Begin By Mid-2015

ARIAD Announces Phase 2 Dose-Ranging Trial Of Iclusig (Ponatinib) To Begin By Mid-2015

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it has concluded consultations with U.

ARIAD Announces Commercialization Agreement For Iclusig In Seven Central And Eastern European Countries

ARIAD Announces Commercialization Agreement For Iclusig In Seven Central And Eastern European Countries

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Angelini Pharma, through the Austrian subsidiary CSC Pharmaceuticals, today announced that ARIAD has granted Angelini exclusive rights to commercialize Iclusig ®...

ARIAD And Otsuka Announce Co-Development And Commercialization Agreement For Iclusig To Treat Leukemias In Japan And Nine Other Asian Countries

ARIAD And Otsuka Announce Co-Development And Commercialization Agreement For Iclusig To Treat Leukemias In Japan And Nine Other Asian Countries

ARIAD Pharmaceuticals, Inc. (ARIAD; NASDAQ: ARIA) and Otsuka Pharmaceutical Co.

ARIAD To Present At The 33rd Annual J.P. Morgan Healthcare Conference

ARIAD To Present At The 33rd Annual J.P. Morgan Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 33 rd Annual J.

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)

Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)

Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.

Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years

Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years

Energy stocks are leading the markets higher, a day after they sparked a selloff.

Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action?

Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action?

Shares of Ariad Pharmaceuticals (ARIA) are down after Credit Suisse downgraded the global oncology company to 'underperform' from 'neutral' and lowered its price target to $6 from $8.

Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers

Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers

Here are today's top research calls.

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib In Chronic-Phase Chronic Myeloid Leukemia From Phase 1 Clinical Trial

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib In Chronic-Phase Chronic Myeloid Leukemia From Phase 1 Clinical Trial

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up data from the Phase 1 trial of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with...

ARIAD Announces Follow-up Data From Phase 1 And PACE Trials Of Ponatinib In Patients With T315I Mutation In Chronic Myeloid Leukemia

ARIAD Announces Follow-up Data From Phase 1 And PACE Trials Of Ponatinib In Patients With T315I Mutation In Chronic Myeloid Leukemia

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced safety and efficacy follow-up data on Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in patients with a baseline T315I mutation from its ...

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial

ARIAD Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig ® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with ...

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Post-Market Leader Stock

Trade-Ideas: ARIAD Pharmaceuticals (ARIA) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a post-market leader candidate

ARIAD Pharmaceuticals (ARIA) Is Strong On High Volume Today

ARIAD Pharmaceuticals (ARIA) Is Strong On High Volume Today

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate

ARIAD Pharmaceuticals (ARIA) Strong On High Relative Volume Today

ARIAD Pharmaceuticals (ARIA) Strong On High Relative Volume Today

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate

ARIAD And STA Announce Approval Of Iclusig (Ponatinib) In Australia

ARIAD And STA Announce Approval Of Iclusig (Ponatinib) In Australia

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), today announced the marketing approval of Iclusig TM (ponatinib) in Australia by the Therapeutic Goods ...

'Mad Money' Lightning Round: A Group to Avoid

'Mad Money' Lightning Round: A Group to Avoid

Cramer says he's not going against Affymetrix, and doesn't want to get back into the sand game.

Jim Cramer's 'Mad Money' Recap: Market 'Losers' Back in the Game

Jim Cramer's 'Mad Money' Recap: Market 'Losers' Back in the Game

Some stocks written off by this market are looking better than ever, Cramer says.

ARIAD Announces Iclusig Data Presentations At Annual American Society Of Hematology Meeting

ARIAD Announces Iclusig Data Presentations At Annual American Society Of Hematology Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the schedule of several data presentations on Iclusig ® (ponatinib) that will take place at the 56th Annual Meeting of the American Society of ...

ARIAD Reports Third Quarter 2014 Financial Results And Development Progress

ARIAD Reports Third Quarter 2014 Financial Results And Development Progress

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter of 2014, including revenue from sales of Iclusig ® (ponatinib).

ARIAD To Present At The Stifel 2014 Healthcare Conference

ARIAD To Present At The Stifel 2014 Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Stifel 2014 Healthcare Conference in New York City.

ARIAD Announces Adoption Of Final Opinion For Iclusig By Committee For Medicinal Products For Human Use In Europe

ARIAD Announces Adoption Of Final Opinion For Iclusig By Committee For Medicinal Products For Human Use In Europe

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted its final opinion on Iclusig ® ...

ARIAD Pharmaceuticals (ARIA) Showing Signs Of Perilous Reversal Today

ARIAD Pharmaceuticals (ARIA) Showing Signs Of Perilous Reversal Today

Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a "perilous reversal" (up big yesterday but down big today) candidate

ARIAD To Webcast Conference Call On Third Quarter 2014 Financial Results

ARIAD To Webcast Conference Call On Third Quarter 2014 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will report its third quarter 2014 financial results on Wednesday, November 5, 2014, before the market opens.

ARIAD Announces Recommendation For Iclusig By The Pharmacovigilance Risk Assessment Committee Of The European Medicines Agency

ARIAD Announces Recommendation For Iclusig By The Pharmacovigilance Risk Assessment Committee Of The European Medicines Agency

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has concluded its review of Iclusig ® ...

ARIAD And Bellicum Announce Revised License Agreement For ARIAD’s Cell-Signaling Technology

ARIAD And Bellicum Announce Revised License Agreement For ARIAD’s Cell-Signaling Technology

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) and Bellicum Pharmaceuticals, Inc.

5 Stocks Under $10 Making Big Moves Higher

5 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Free Fall Continues for Freddie Mac, Fannie Mae

Free Fall Continues for Freddie Mac, Fannie Mae

Today's top-performing billionaire stock picks midday are Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Neonode, Inc (NASDAQ:NEON) and AutoNation, Inc. (NYSE:AN). The losers are Freddie Mac / Federal H...

Why Ariad Pharmaceuticals (ARIA) Stock Is Spiking Today

Why Ariad Pharmaceuticals (ARIA) Stock Is Spiking Today

Ariad Pharmaceuticals (ARIA) shares are up after its lung cancer treatment was given a 'breakthrough therapy' designation by the FDA.

ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant To Crizotinib

ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant To Crizotinib

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its investigational cancer medicine, AP26113, has received Breakthrough Therapy designation by the U.